{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:41:21Z","timestamp":1787240481549,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ahj.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T01:36:20Z","timestamp":1731807380000},"page":"60-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-5307","authenticated-orcid":false,"given":"Alexander C.","family":"Fanaroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit N.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.11.005_bib0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ahj.2021.04.016","article-title":"Seeking patient-centered trial outcomes: the case for days alive out of hospital","volume":"248","author":"Faggioni","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004755","article-title":"Days alive and out of hospital: exploring a patient-centered, pragmatic outcome in a clinical trial of patients with acute coronary syndromes","volume":"11","author":"Fanaroff","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.11.005_bib0003","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/eht013","article-title":"Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy","volume":"34","author":"Verheugt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0004","doi-asserted-by":"crossref","first-page":"e1484","DOI":"10.4244\/EIJ-D-19-00953","article-title":"Statistical methods for composite endpoints","volume":"16","author":"Hara","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2024.11.005_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2017.03.046","article-title":"Antithrombotic agents for secondary prevention after acute coronary syndromes: a systematic review and network meta-analysis","volume":"214","author":"Fanaroff","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2024.11.005_bib0006","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.amjcard.2015.05.058","article-title":"Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome","volume":"116","author":"Bavishi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2024.11.005_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2024.11.005_bib0008","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.11.005_bib0009","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehu262","article-title":"Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial","volume":"36","author":"Bakal","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0011","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jacc.2018.03.517","article-title":"Home-time after discharge among patients hospitalized with heart failure","volume":"71","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.11.005_bib0012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ahj.2011.08.003","article-title":"Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program","volume":"162","author":"Ariti","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0013","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/STROKEAHA.115.011599","article-title":"Assessment of home-time after acute ischemic stroke in Medicare beneficiaries","volume":"47","author":"Fonarow","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2024.11.005_bib0014","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.11.005_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000447396","article-title":"Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox","volume":"136","author":"Beigel","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2024.11.005_bib0017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ahj.2021.03.016","article-title":"Days alive out of hospital in heart failure: insights from the PARADIGM-HF and CHARM trials","volume":"241","author":"Chen","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.11.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005858","article-title":"Alirocumab reduces total hospitalizations and increases days alive and out of hospital in the ODYSSEY OUTCOMES trial","volume":"12","author":"Szarek","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2024.11.005_bib0019","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/CIRCULATIONAHA.119.043754","article-title":"Hospitalization among patients with atrial fibrillation and a recent acute coronary syndrome or percutaneous coronary intervention treated with Apixaban or Aspirin","volume":"140","author":"Vora","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.11.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004310","article-title":"Use of chronic oral anticoagulation and associated outcomes among patients undergoing percutaneous coronary intervention","volume":"5","author":"Secemsky","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.11.005_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.11.005_bib0022","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/CIRCULATIONAHA.119.043754","article-title":"Hospitalization among patients with atrial fibrillation and a recent acute coronary syndrome or percutaneous coronary intervention treated with Apixaban or Aspirin","volume":"140","author":"Vora","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.11.005_bib0023","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jcin.2019.02.007","article-title":"Timing and causes of unplanned readmissions after percutaneous coronary interventions: insights from the nationalwide readmission database","volume":"12","author":"Kwok","year":"2019","journal-title":"JACC Cardiovasc Interv"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324002977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T17:32:45Z","timestamp":1733592765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324002977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"alternative-id":["S0002870324002977"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.11.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}